- Home
- TARS vs WSBC Comparison
TARS vs WSBC Comparison
Compare TARS & WSBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TARS | WSBC |
|---|---|---|
| Founded | 2016 | 1870 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.6B |
| IPO Year | 2020 | 1994 |
Fundamental Metrics
Financial Performance| Metric | TARS | WSBC |
|---|---|---|
| Price | $68.26 | $39.10 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 8 |
| Target Price | ★ $99.80 | $44.14 |
| AVG Volume (30 Days) | 652.8K | ★ 714.2K |
| Earning Date | 11-03-2026 | 10-21-2026 |
| Dividend Yield | N/A | ★ 3.88% |
| EPS Growth | ★ 48.21 | N/A |
| EPS | N/A | ★ 1.79 |
| Revenue | ★ $451,360,000.00 | N/A |
| Revenue This Year | $61.17 | $10.41 |
| Revenue Next Year | $26.47 | $6.98 |
| P/E Ratio | ★ N/A | $21.78 |
| Revenue Growth | ★ 146.71 | N/A |
| 52 Week Low | $53.89 | $29.57 |
| 52 Week High | $91.53 | $43.02 |
Technical Indicators
Market Signals| Indicator | TARS | WSBC |
|---|---|---|
| Relative Strength Index (RSI) | 39.23 | 60.50 |
| Support Level | $60.95 | $38.79 |
| Resistance Level | $74.51 | $41.45 |
| Average True Range (ATR) | 3.34 | 0.74 |
| MACD | -0.37 | 0.35 |
| Stochastic Oscillator | 2.22 | 95.15 |
Price Performance
Historical ComparisonAbout TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
About WSBC WesBanco Inc.
Wesbanco Inc is a bank holding company. Through its subsidiaries, it offers a full range of financial services, including retail banking, corporate banking, personal and corporate trust services, brokerage services, mortgage banking, and insurance. WesBanco operates one commercial bank, WesBanco Bank, which runs scores of branches. The company's reportable segments are Community Banking, which derives key revenue, and Trust and Investment Services. The Community Banking segment offers various banking products and services through various delivery channels, including commercial demand, individual demand, and time deposit accounts; commercial, mortgage, and individual installment loans; and certain non-traditional offerings, such as insurance and securities brokerage services.